Axsome Therapeutics, Inc.
AXSM
Κατάταξη σε μετοχές
#2361
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Τιμή μετοχής
$159.65
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$8.36B
Αλλαγή (1 ημέρα)
2.46%
Αλλαγή (1 έτος)
21.51%
Χώρα
US
Εμπόριο Axsome Therapeutics, Inc. (AXSM)
Κατηγορία
Healthcare
Κέρδη για την Axsome Therapeutics, Inc. (AXSM)
Κέρδη τον Jun 2026 TTM: $-191.09M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Axsome Therapeutics, Inc., τα τρέχοντα κέρδη της εταιρείας είναι $-191.09M. Το 2023, η εταιρεία παρουσίασε κέρδη $-238.28M, μείωση σε σύγκριση με των κερδών του 2022 που ήταν $-187.13M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Axsome Therapeutics, Inc. από 2013 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-191.09M | -33.45% |
| 2024 | $-287.13M | 20.50% |
| 2023 | $-238.28M | 27.33% |
| 2022 | $-187.13M | 43.50% |
| 2021 | $-130.40M | 26.73% |
| 2020 | $-102.90M | 50.56% |
| 2019 | $-68.35M | 120.71% |
| 2018 | $-30.97M | 6.99% |
| 2017 | $-28.94M | 6.40% |
| 2016 | $-27.20M | 157.60% |
| 2015 | $-10.56M | 75.98% |
| 2014 | $-6.00M | 176.95% |
| 2013 | $-2.17M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $5.27B | -2,860.48% |
US
|
|
| $-3.09B | 1,515.50% |
US
|
|
| $-4.02B | 2,001.77% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,120.82% |
NL
|
